Roche's Cindy Perettie named EVP of Kite

17 May 2023
cindy_perettie_gilead_kite_large-1

Gilead Sciences (Nasdaq: GILD) has announced that Cindy Perettie will join the firm as executive vice president of its subsidiary company Kite, overseeing the cell therapy business.

Ms Perettie will also become a member of Gilead’s senior leadership team, effective May 30, bringing with her extensive experience in oncology, which is now a major focus for the Californian biotech company.

"The cell therapy business continues to play an important role in Gilead’s ambition to become a top oncology company"Most recently, Ms Perettie was head of Roche’s (ROG: SIX) Molecular Lab Solutions, where she oversaw the polymerase chain reaction and sequencing business. Prior to that, she was chief executive at Roche-owned Foundation Medicine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology